Clinical Trials
Phase II clinical trial in neuropathic pain begins
Published in Obesity and Diabetes Week, March 13th, 2006
This is the first study of bicifadine in patients with neuropathic pain. The trial is a randomized, multiple-dose, open-label, 2-phase overlap trial designed to assess the efficacy and safety of bicifadine and potential interactions of bicifadine and oxycodone used concurrently. DOV expects to complete dosing in the third quarter of this year.
The clinical trial will randomize 50 patients with painful diabetic neuropathy into 2 parallel 4-week treatment groups. In...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Endocrinology
Insulin stimulates L-carnitine accumulation in human skeletal muscle - Natural Products
Salacia oblonga root improves cardiac lipid metabolism in Zucker diabetic fatty rats - Obesity Pathogenesis
Adipokine expression profile in adipocytes increases with obesity and hyperinsulinemia - Obesity Therapy
Morbid obesity therapy with SAGB is less expensive and more effective - Type 2 Diabetes
Statins use related to increased LPL activity and results in TRL particle delipidation - Aesthetic Medicine
Despite risks, adults not shying away from cosmetic surgery and other treatments - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
